These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 26271033)

  • 1. Biochemical and Immunological Characterization of Truncated Fragments of the Receptor-Binding Domains of C. difficile Toxin A.
    Huang JH; Shen ZQ; Lien SP; Hsiao KN; Leng CH; Chen CC; Siu LK; Chong PC
    PLoS One; 2015; 10(8):e0135045. PubMed ID: 26271033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant lipoprotein-based vaccine candidates against C. difficile infections.
    Huang JH; Wu CW; Lien SP; Leng CH; Hsiao KN; Liu SJ; Chen HW; Siu LK; Chong P
    J Biomed Sci; 2015 Aug; 22(1):65. PubMed ID: 26245825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional properties of the carboxy-terminal host cell-binding domains of the two toxins, TcdA and TcdB, expressed by Clostridium difficile.
    Dingle T; Wee S; Mulvey GL; Greco A; Kitova EN; Sun J; Lin S; Klassen JS; Palcic MM; Ng KK; Armstrong GD
    Glycobiology; 2008 Sep; 18(9):698-706. PubMed ID: 18509107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of a neutralizing antibody helps identify structural features critical for binding of
    Kroh HK; Chandrasekaran R; Rosenthal K; Woods R; Jin X; Ohi MD; Nyborg AC; Rainey GJ; Warrener P; Spiller BW; Lacy DB
    J Biol Chem; 2017 Sep; 292(35):14401-14412. PubMed ID: 28705932
    [No Abstract]   [Full Text] [Related]  

  • 5. The recombinant Lactococcus lactis oral vaccine induces protection against C. difficile spore challenge in a mouse model.
    Guo S; Yan W; McDonough SP; Lin N; Wu KJ; He H; Xiang H; Yang M; Moreira MA; Chang YF
    Vaccine; 2015 Mar; 33(13):1586-95. PubMed ID: 25698490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Binding of Clostridium difficile toxins to human milk oligosaccharides.
    El-Hawiet A; Kitova EN; Kitov PI; Eugenio L; Ng KK; Mulvey GL; Dingle TC; Szpacenko A; Armstrong GD; Klassen JS
    Glycobiology; 2011 Sep; 21(9):1217-27. PubMed ID: 21610194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clostridium difficile chimeric toxin receptor binding domain vaccine induced protection against different strains in active and passive challenge models.
    Tian JH; Glenn G; Flyer D; Zhou B; Liu Y; Sullivan E; Wu H; Cummings JF; Elllingsworth L; Smith G
    Vaccine; 2017 Jul; 35(33):4079-4087. PubMed ID: 28669616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant Clostridium difficile toxin fragments as carrier protein for PSII surface polysaccharide preserve their neutralizing activity.
    Romano MR; Leuzzi R; Cappelletti E; Tontini M; Nilo A; Proietti D; Berti F; Costantino P; Adamo R; Scarselli M
    Toxins (Basel); 2014 Apr; 6(4):1385-96. PubMed ID: 24759173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An optimized, synthetic DNA vaccine encoding the toxin A and toxin B receptor binding domains of Clostridium difficile induces protective antibody responses in vivo.
    Baliban SM; Michael A; Shammassian B; Mudakha S; Khan AS; Cocklin S; Zentner I; Latimer BP; Bouillaut L; Hunter M; Marx P; Sardesai NY; Welles SL; Jacobson JM; Weiner DB; Kutzler MA
    Infect Immun; 2014 Oct; 82(10):4080-91. PubMed ID: 25024365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a recombinant toxin fragment vaccine for Clostridium difficile infection.
    Karczewski J; Zorman J; Wang S; Miezeiewski M; Xie J; Soring K; Petrescu I; Rogers I; Thiriot DS; Cook JC; Chamberlin M; Xoconostle RF; Nahas DD; Joyce JG; Bodmer JL; Heinrichs JH; Secore S
    Vaccine; 2014 May; 32(24):2812-8. PubMed ID: 24662701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding and entry of Clostridium difficile toxin B is mediated by multiple domains.
    Manse JS; Baldwin MR
    FEBS Lett; 2015 Dec; 589(24 Pt B):3945-51. PubMed ID: 26602083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular cloning, overexpression in Escherichia coli, and purification of 6x his-tagged C-terminal domain of Clostridium difficile toxins A and B.
    Letourneur O; Ottone S; Delauzun V; Bastide MC; Foussadier A
    Protein Expr Purif; 2003 Oct; 31(2):276-85. PubMed ID: 14550648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel fusion protein containing the receptor binding domains of C. difficile toxin A and toxin B elicits protective immunity against lethal toxin and spore challenge in preclinical efficacy models.
    Tian JH; Fuhrmann SR; Kluepfel-Stahl S; Carman RJ; Ellingsworth L; Flyer DC
    Vaccine; 2012 Jun; 30(28):4249-58. PubMed ID: 22537987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of Oligosaccharides in Human Milk Bound onto the Toxin A Carbohydrate Binding Site of Clostridium difficile.
    Nguyen TT; Kim JW; Park JS; Hwang KH; Jang TS; Kim CH; Kim D
    J Microbiol Biotechnol; 2016 Apr; 26(4):659-65. PubMed ID: 26718473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toll-like receptor 5-dependent immunogenicity and protective efficacy of a recombinant fusion protein vaccine containing the nontoxic domains of Clostridium difficile toxins A and B and Salmonella enterica serovar typhimurium flagellin in a mouse model of Clostridium difficile disease.
    Ghose C; Verhagen JM; Chen X; Yu J; Huang Y; Chenesseau O; Kelly CP; Ho DD
    Infect Immun; 2013 Jun; 81(6):2190-6. PubMed ID: 23545305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A DNA vaccine targeting TcdA and TcdB induces protective immunity against Clostridium difficile.
    Zhang BZ; Cai J; Yu B; Hua Y; Lau CC; Kao RY; Sze KH; Yuen KY; Huang JD
    BMC Infect Dis; 2016 Oct; 16(1):596. PubMed ID: 27770789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunisation of mares with binding domains of toxins A and B of Clostridium difficile elicits serum and colostral antibodies that block toxin binding.
    Artiushin S; Timoney JF; Fettinger M; Fallon L; Rathgeber R
    Equine Vet J; 2013 Jul; 45(4):476-80. PubMed ID: 23206274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral Immunization with Nontoxigenic Clostridium difficile Strains Expressing Chimeric Fragments of TcdA and TcdB Elicits Protective Immunity against C. difficile Infection in Both Mice and Hamsters.
    Wang Y; Wang S; Bouillaut L; Li C; Duan Z; Zhang K; Ju X; Tzipori S; Sonenshein AL; Sun X
    Infect Immun; 2018 Nov; 86(11):. PubMed ID: 30150259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant antigens based on toxins A and B of Clostridium difficile that evoke a potent toxin-neutralising immune response.
    Maynard-Smith M; Ahern H; McGlashan J; Nugent P; Ling R; Denton H; Coxon R; Landon J; Roberts A; Shone C
    Vaccine; 2014 Feb; 32(6):700-5. PubMed ID: 24342251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The protective effect of recombinant Lactococcus lactis oral vaccine on a Clostridium difficile-infected animal model.
    Yang XQ; Zhao YG; Chen XQ; Jiang B; Sun DY
    BMC Gastroenterol; 2013 Jul; 13():117. PubMed ID: 23865596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.